If you have seen headlines about colorectal cancer increasing in younger adults, you might be wondering how alarmed to actually be. The short answer: the trend is real, it is well-documented, and it is happening across multiple countries. The longer answer requires looking at what the data actually says, because there is a wide gap between 'rates are going up' and 'you should panic.' This article walks through the epidemiological evidence, the birth cohort patterns, the age group breakdowns, and the leading hypotheses for why this is happening. It is a data overview, not a symptom guide or a deep dive into causes.
How much has colorectal cancer in young adults actually increased?
The foundational research comes from Rebecca Siegel and colleagues at the American Cancer Society. Their work, published across multiple papers in the Journal of the National Cancer Institute, showed that colorectal cancer incidence rates in adults aged 20 to 49 began rising around 1994 after decades of decline across all age groups. From 2011 to 2019, incidence in adults under 50 increased by approximately 1.9% per year (Siegel et al., JNCI, 2023).
To put that in perspective: among adults 50 and older, colorectal cancer rates have been declining steadily since the mid-1980s, largely due to widespread screening with colonoscopy and removal of precancerous polyps. The under-50 trend is moving in the opposite direction. By 2030, projections suggest that young-onset disease will account for roughly 11% of all colon cancer diagnoses and 23% of all rectal cancer diagnoses in the United States (Siegel et al., JNCI Monographs, 2023).
These are relative increases from a low base. The absolute risk of colorectal cancer for any given person under 50 remains small. But the trend line is consistent, it has been validated in independent datasets, and it is not slowing down.
What is the birth cohort effect in young-onset colorectal cancer?
One of the most striking findings in recent research is the birth cohort pattern. A 2024 analysis published in Lancet Gastroenterology & Hepatology examined colorectal cancer incidence data across 27 countries and found a consistent pattern: each successive birth cohort born after approximately 1960 has a higher age-adjusted colorectal cancer risk than the cohort before it.
People born in the 1990s face roughly four times the risk of early-onset colorectal cancer compared to those born in the 1960s. This pattern held across geographically and ethnically diverse populations. The consistency of the signal across countries is one of the strongest pieces of evidence that something about modern environments, not genetics alone, is driving the increase.
A birth cohort effect means that risk tracks with when you were born, not simply how old you are. This distinguishes it from an age effect (where everyone at a given age would have the same risk regardless of era) or a period effect (where something happening at a specific calendar time affects everyone equally). The birth cohort pattern points toward early-life or cumulative exposures that differ systematically between generations.
âšī¸A birth cohort effect means something about growing up in a particular era changes your lifetime disease risk. For young-onset CRC, the cohort effect suggests that exposures during childhood or adolescence (dietary patterns, antibiotic use, environmental chemicals, microbiome development, or some combination) may be relevant. This is still hypothesis-level, not established causation.
Is rectal cancer rising faster than colon cancer in young adults?
Yes, and this is one of the more puzzling aspects of the trend. Among adults under 50, rectal cancer incidence has been increasing at a faster rate than colon cancer. From 2011 to 2019, rectal cancer incidence in this age group rose by approximately 3.2% per year, compared to roughly 1.4% per year for colon cancer (Siegel et al., JNCI, 2023).
This pattern has also been observed internationally. A global analysis published in Gut in 2022 confirmed the disproportionate rise in rectal cancer among younger adults across multiple continents. The reasons for this anatomic site predilection are unclear. Hypotheses include differences in the rectal mucosal microbiome, differences in blood supply and exposure to bile acids, and the closer proximity of rectal tissue to certain environmental exposures. None of these explanations are proven.
The clinical implications are significant. Rectal cancer carries its own set of treatment challenges, including higher rates of needing radiation therapy, potential impacts on bowel, sexual, and urinary function, and in some cases the need for permanent colostomy. Early detection matters for all colorectal cancers, but the consequences of late-stage rectal cancer in a 30- or 40-year-old are particularly significant given the decades of life ahead.
Which countries are seeing the increase in young-onset colorectal cancer?
The trend is not limited to the United States. Studies have documented rising young-onset CRC incidence in Canada, the United Kingdom, Australia, Germany, Denmark, Sweden, and multiple other high-income countries. A 2019 systematic review in Lancet Gastroenterology & Hepatology analyzed data from 43 countries and found increasing early-onset CRC trends in most high-income nations (Vuik et al., 2019).
Some low- and middle-income countries are also seeing increases, though data quality varies. Countries with rapidly westernizing diets and lifestyles appear to be experiencing similar shifts, which has fueled hypotheses about dietary and environmental factors. However, the international data is complicated by differences in cancer registry completeness, screening practices, and diagnostic capabilities.
The geographic breadth of the trend is one reason researchers suspect the cause is something widespread in modern environments rather than a localized exposure. Whatever is driving this is present across multiple continents.
Why did the ACS change colorectal cancer screening to start at 45?
In 2018, the American Cancer Society updated its colorectal cancer screening guideline to recommend that average-risk adults begin screening at age 45 rather than 50. This was a significant shift, driven in large part by the rising incidence data in the 45-to-49 age group specifically (Wolf et al., CA: A Cancer Journal for Clinicians, 2018).
The U.S. Preventive Services Task Force (USPSTF) followed in 2021, also lowering their recommended screening start age to 45 with a B recommendation. The qualifying options include colonoscopy every 10 years, annual fecal immunochemical test (FIT), multitarget stool DNA testing (Cologuard) every 3 years, CT colonography every 5 years, or flexible sigmoidoscopy every 5 years (USPSTF, JAMA, 2021).
It is worth noting that the screening age change addresses only a portion of the at-risk population. The steepest relative increases have been in adults in their 20s and 30s, for whom routine screening is not recommended absent symptoms or family history. For this group, symptom awareness and timely medical evaluation remain the primary tools for early detection.
â ī¸Screening guidelines are for average-risk, asymptomatic individuals. If you have symptoms (rectal bleeding, persistent change in bowel habits, unexplained weight loss, iron-deficiency anemia) or a family history of colorectal cancer or advanced polyps, screening recommendations may begin earlier and be more intensive. Talk to your doctor about your specific risk profile.
What is causing the rise in young-onset colorectal cancer?
This is the central question in the field, and the honest answer is: we do not know yet. No single factor has been identified as the cause. Researchers have proposed multiple hypotheses, and it is likely that several factors interact. Here are the leading candidates, presented with their current level of evidence.
Diet and ultra-processed food consumption are among the most frequently cited hypotheses. Diets high in ultra-processed foods, red and processed meat, and low in fiber have been associated with higher colorectal cancer risk in large observational studies. A 2022 study in the BMJ found that higher ultra-processed food consumption was associated with increased colorectal cancer risk, with the association particularly pronounced in men and for distal colon cancer. However, observational studies cannot prove causation, and the specific dietary component responsible (if any single component exists) has not been identified.
Obesity and metabolic dysfunction are another major area of investigation. Obesity rates have risen in parallel with young-onset CRC rates across many of the same populations. Obesity is an established risk factor for colorectal cancer in older adults, and the metabolic effects of visceral adiposity (chronic inflammation, insulin resistance, altered hormone levels) are biologically plausible contributors. But the correlation is imperfect. Not all countries with rising obesity have seen the same CRC increases, and the trend is also occurring in people who are not obese.
Gut microbiome changes are an area of active research. Specific bacterial species (including colibactin-producing E. coli and Fusobacterium nucleatum) have been found in higher abundance in colorectal tumor tissue compared to healthy tissue. Whether microbiome shifts in younger generations are contributing to the trend is a plausible but unproven hypothesis.
Environmental exposures, including early-life antibiotic use, changes in the food supply, environmental chemicals (such as PFAS and microplastics), and sedentary behavior, are all under investigation. The birth cohort effect is consistent with exposures that have changed over recent decades, but narrowing down which exposures matter most has proven difficult. Large prospective cohort studies, including the NCI's PROSPECT initiative specifically focused on early-onset colorectal cancer, are underway but results are years away.
What does this mean for you practically?
If you are under 50, the rising incidence trend does not mean you are likely to get colorectal cancer. The absolute risk for any individual young adult remains low. What it does mean is that colorectal cancer should not be automatically dismissed as a possibility when a young person presents with concerning symptoms.
If you are 45 or older and have not been screened, talk to your doctor about starting. If you have a family history of colorectal cancer or advanced polyps, screening may be recommended earlier. If you have symptoms like rectal bleeding, a persistent change in bowel habits lasting more than a few weeks, unexplained weight loss, or iron-deficiency anemia, seek evaluation regardless of your age.
Tools like GLP1Gut can help you track symptoms and bring organized data to your doctor, which is useful for documenting patterns over time. But the most important step, if you are concerned, is a conversation with a clinician who takes your symptoms seriously.
If I am under 45 and have no symptoms or family history, should I get screened?
Current guidelines do not recommend routine screening for average-risk adults under 45 without symptoms or family history. However, if you have concerning symptoms at any age, that is a reason to see a doctor regardless of screening guidelines.
Is the rise in young-onset CRC just better detection?
Improved detection likely plays a small role, but most researchers believe the increase is predominantly a true rise in incidence. The birth cohort effect and the consistency of the trend across countries with different diagnostic practices support this interpretation.
Does colorectal cancer in young people behave differently?
Young-onset colorectal cancers are more likely to be diagnosed at an advanced stage (partly due to diagnostic delays) and are more likely to have certain molecular features, including microsatellite instability and signet ring histology. Whether these biological differences are prognostically meaningful independent of stage is still being studied.